Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lantern Pharma is a clinical-stage AI-driven oncology company developing targeted therapies for cancer patients with specific genetic profiles. The company operates a proprietary RADR AI platform that analyzes over 25 billion oncology data points to identify drug candidates and patient populations, currently advancing multiple programs including LP-300 (pancreatic/ovarian cancer) and LP-184 (glioblastoma/solid tumors). With no revenue generation and negative cash flow, the stock trades on clinical trial milestones, partnership announcements, and capital runway visibility.
Lantern operates a capital-intensive R&D model with no current revenue, burning cash to advance clinical trials. The business thesis centers on using AI/machine learning to reduce drug development costs and timelines versus traditional pharma, targeting orphan indications with smaller patient populations that require less expensive trials. Monetization depends on either: (1) advancing drugs through Phase 2/3 trials and partnering with larger pharma for commercialization in exchange for upfront payments, milestones, and royalties, or (2) achieving regulatory approval and commercializing independently in niche oncology markets. The RADR platform provides potential competitive advantage by identifying biomarker-driven patient populations with higher response rates, theoretically improving trial success probability. Pricing power would come from orphan drug designations and lack of treatment alternatives in targeted indications.
Clinical trial data readouts and interim analysis results for LP-300, LP-184, and LP-184 ADC programs
FDA regulatory decisions including IND clearances, Fast Track designations, and orphan drug status grants
Partnership announcements with larger pharmaceutical companies for co-development or licensing deals
Cash runway updates and financing events (equity raises, dilution concerns given negative FCF)
Competitive clinical data from rival therapies in pancreatic cancer, glioblastoma, and targeted oncology spaces
AI platform validation through third-party collaborations or publications demonstrating RADR predictive accuracy
Binary clinical trial outcomes with high failure rates - oncology drugs have ~5% probability of Phase 1 to approval success, and single negative readout can eliminate program value
Regulatory pathway uncertainty for AI-driven drug development as FDA frameworks for machine learning-based patient selection remain evolving
Capital intensity and dilution risk - company must access equity markets repeatedly to fund operations, with each raise diluting existing shareholders given negative cash generation
Competitive pressure from well-funded large pharma and biotech developing therapies in same indications (pancreatic cancer, glioblastoma) with superior resources
Larger oncology players (Roche, Merck, Bristol Myers) developing competing targeted therapies with faster timelines and greater trial enrollment capacity
Alternative AI-driven drug discovery platforms from companies like Recursion Pharmaceuticals, Exscientia, and Insitro potentially invalidating Lantern's competitive moat
Breakthrough therapies in targeted oncology (CAR-T, bispecifics) could render small molecule approaches obsolete in certain indications
Cash runway risk - with -57.7% FCF yield and no revenue, company faces ongoing dilution or potential inability to complete trials if capital markets close
Negative ROE of -126% and ROA of -138.8% reflect value destruction at current stage, requiring successful clinical outcomes to justify continued investment
Low market cap increases vulnerability to delisting risk if stock price remains depressed, limiting institutional ownership and liquidity
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending follows scientific timelines rather than economic cycles. However, financing conditions and investor risk appetite for speculative growth stocks correlate with economic sentiment, affecting ability to raise capital. Oncology drug demand (post-approval) is non-discretionary and recession-resistant, but company is years from commercialization.
High interest rates negatively impact valuation through two mechanisms: (1) Higher discount rates compress NPV of distant future cash flows, which for pre-revenue biotech may be 5-10 years out, making the stock highly sensitive to risk-free rate changes. (2) Rising rates reduce investor appetite for speculative growth equities, tightening access to capital markets for equity raises that fund operations. With -138.8% ROA and cash burn, the company requires periodic financing, making cost of capital critical. Rate cuts would improve valuation multiples and financing conditions.
Minimal direct credit exposure given negligible debt (0.01 D/E ratio) and no commercial operations requiring trade credit. However, equity market credit conditions indirectly affect ability to raise growth capital. Tight credit markets reduce institutional investor allocations to high-risk biotech, while loose conditions improve financing availability. The 3.33 current ratio suggests adequate near-term liquidity, but sustained operations depend on equity markets remaining receptive to dilutive raises.
growth - Attracts speculative growth investors and biotech specialists willing to accept binary risk/reward profiles for potential multi-bagger returns if clinical trials succeed. Not suitable for value or income investors given no earnings, dividends, or tangible book value. Momentum traders enter around catalyst events (trial data, FDA decisions). Typical holders include retail speculators, dedicated healthcare funds, and venture-style public market investors with high risk tolerance and long time horizons.
high - Clinical-stage biotech exhibits extreme volatility with stock moves of 20-50% common on trial data releases. The -39.3% one-year return and -39.6% six-month return reflect typical drawdown risk. Low market cap and limited institutional ownership amplify price swings. Beta likely exceeds 2.0x relative to broader market, with idiosyncratic risk dominating systematic risk. Volatility spikes around scheduled data readouts and financing announcements.
